| Assessment Status | Rapid Review Complete |
| HTA ID | 21051 |
| Drug | Mometasone furoate plus olopatadine |
| Brand | Ryaltris® |
| Indication | Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2021 |
| Rapid review completed | 22/12/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that mometasone furoate plus olopatadine (Ryaltris®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
